Pinned Tweet
Phase III clinical trial of pediatric subjects with PMM2-CDG begins crossover to open label epalrestat prnewswire.com/news-releases…
Maggie's Pearl retweeted
Wrapping up an enlightening Rare Disease Caucus briefing on "Novel Approaches to Drug Development for Small Rare Disease Populations—and the Policies that Can Drive Them." A huge thank you to our insightful speakers (Adora Ndu, @eperlste , Dominique Pichard, Christine Waggoner, Annie Kennedy) Let's keep the momentum going and register for our #ScientificWorkshop2024 bit.ly/3crHRGd
Maggie's Pearl retweeted
Our collaborative work with the Tamas Kozicz and @EvaMorava team describing a new cortical brain organoid model of PMM2 Congenital Disorder of Glycosylation led by @Radenkovic_S and @budhraja_rohit has just been published in @CellReports #glycotime @FrontierCDG
Maggie's Pearl retweeted
In the latest collaboration efforts led by @kilroykishore and @Lab_Pandey , we identified complement4 as a novel biomarker for PMM2 deficiency! @FrontierCDG @CdgHub
Highlighting our latest work on discovery and validation of a novel glycopeptide #biomarker for PMM2-CDG – the most common congenital disorder of glycosylation. Just published in @JCI_insight #teammassspec #glycotime
Maggie's Pearl retweeted
Our pivotal Phase 3 trial advances to open label!
Phase III clinical trial of pediatric subjects with PMM2-CDG begins crossover to open label epalrestat prnewswire.com/news-releases…
Maggie's Pearl retweeted
A collaboration between @PerlaraPBC, Maggie’s Cure, and @MayoClinic has announced significant progress in their Phase III trial of epalrestat, an experimental drug meant to combat a rare genetic disease. Read more here:
prnewswire.com/news-releases…
#MayoClinic #Innovation #Genetics
Maggie's Pearl retweeted
🎉 That‘s a wrap! Thank you everyone!
🤝 Together, we‘ve expanded our knowledge, challenged preconceptions, and strengthened the bonds within our community.
Let‘s keep pushing the boundaries and advocating for the CDG community.
#6thWorldConferenceonCDG
Maggie's Pearl retweeted
Mayo Clinic discovery leads to life-changing treatment for young girl with ultra-rare disease mayocl.in/3oLNSZ6 #MedGeneEd23
Maggie's Pearl retweeted
Check out the tweetorial of our #FCDGC investigators at @rarediseasesnet for insights into new potential treatment for #PMM2-#CDG, now a phase III clinical trial.
After 4 years our article is finally out! Many thanks to supervisors @EvaMorava and @VIBMetaboCoreLV ! We investigate the link between abnormal glycosylation and polyol metabolism, and show targeting polyol metbolism results in improved glycosylation in PMM2-CDG! Check it out👇🏻
Maggie's Pearl retweeted
After 4 years our article is finally out! Many thanks to supervisors @EvaMorava and @VIBMetaboCoreLV ! We investigate the link between abnormal glycosylation and polyol metabolism, and show targeting polyol metbolism results in improved glycosylation in PMM2-CDG! Check it out👇🏻
Online now: Tracer metabolomics reveals the role of aldose reductase in glycosylation dlvr.it/Spwbyx
Maggie's Pearl retweeted
From made-to-order genetic therapies to model organisms engineered to be ‘patient avatars’, the technology exists right now to save patients with rare diseases go.nature.com/3JOQ5Jv
Maggie's Pearl retweeted
Personalized medicine is having its day
From made-to-order genetic therapies to model organisms engineered to be ‘patient avatars’, the technology exists right now to save patients with rare diseases go.nature.com/3JOQ5Jv
Maggie's Pearl retweeted
.@MayoClinic entered into a know-how agreement with @epalrestat in 2021 to develop the first platform therapy for a group of related genetic inborn errors of metabolism called PMM2-CDG. Today that therapy is having real impact! Read more: individualizedmedicineblog.m… #RareDiseaseDay
Maggie's Pearl retweeted
Months after Maggie started taking an experimental drug for her ultra-rare genetic disease, she traded in her wheelchair for a walker. The 9-year-old also became better at feeding herself, her speech improved and she started coloring in the lines. mayocl.in/3xWxTrX
Maggie's Pearl retweeted
Meet Maggie Carmichael, a patient with a #CongenitalDisorderOfGlycosylation who is receiving a new treatment pioneered by Eva Morava-Kozicz, MD, PhD, principal investigator of @FrontierCDG, and collaborators: individualizedmedicineblog.m…
#RareDiseaseDay #RDDNIH
A Mayo Clinic discovery has led to a life-changing treatment for young girl with an ultra-rare disease. Read more: mayocl.in/3kwNeMJ #RareDiseaseDay
Maggie's Pearl retweeted
A Mayo Clinic discovery has led to a life-changing treatment for young girl with an ultra-rare disease. Read more: mayocl.in/3kwNeMJ #RareDiseaseDay
Maggie's Pearl retweeted
Maggie’s Pearl Initiates Phase III Clinical Trial for Treatment of Patients with PMM2-CDG prnewswire.com/news-releases…
Maggie’s Pearl Initiates Phase III Clinical Trial for Treatment of Patients with PMM2-CDG prnewswire.com/news-releases…
To learn more, please reach out to the Clinical Research Coordinator at Mayo Clinic who is managing study enrollment: [email protected], 507-266-9619
1
185
Maggie's Pearl retweeted
The 40-patient placebo-controlled Phase 3 study of epalrestat for the treatment of PMM2-CDG is actively recruiting clinicaltrials.gov/ct2/show/…























